Zinc(2+)

HCID 32051CAS 1492823-75-2

基本情報

標準SMILES
[Zn+2]
InChIKey
PTFCDOFLOPIGGS-UHFFFAOYSA-N
分子式
Zn+2
平均分子量
65.4 g/mol
単同位体質量
63.92804504

概要

Zinc(2+) is a monoatomic dication, a divalent metal cation and a zinc cation. It has a role as a cofactor and a human metabolite.

名称と識別子

優先名称
Zinc(2+)
IUPAC
zinc(2+)
英語名
zinc(+2) cation
分子式
Zn+2
分子量
65.39

名称と別名

zinc ionzinc(2+)Zinc cation23713-49-7Zinc, ion (Zn2+)zinc(II)Zinc ionsZinc ion(2+)Zinc 2+13S1S8SF37Zn(II)CHEBI:29105
名称をさらに表示
亜鉛イオン
RefChem:1101172CHEBI:27365CHEBI:63056Velmanase Alfa9025-42-7Topostin BZn2+Lamazym

データベース識別子

CAS
1492823-75-2、23713-49-7、7440-66-6
PubChem CID
32051
DTXSID
DTXSID40920495
ChEMBL
CHEMBL1236970
ChEBI
CHEBI:29105
UNII
13S1S8SF37
Nikkaji
J3.745.259I

物性

構造計算による物性

極性表面積
0 Ų
水素結合供与体数
0
水素結合受容体数
0
回転可能結合数
0
重原子数
1

実験および物理化学的性質

Melting Point419.5 °C
Physical DescriptionSolid

物理化学的性質

EPAの化学物質情報
Zinc, ion (Zn2+) (23713-49-7)

安全と法規制

安全と保護具

Minimum Risk LevelIntermediate Oral: 0.3 mg/kg/day (L134) Chronic Oral: 0.3 mg/kg/day (L134)

毒性情報

TreatmentZinc poisoning is treated symptomatically, often by administering fluids such as water or milk, or with gastric lavage. (L49)
Health Effects · 1 件

Chronic exposure to zinc causes anemia, atazia, lethargy, and decreases the level of HDL (good) cholesterol in the body. It is also believed to cause pancreatic and reproductive damages. Unbalanced levels of copper and zinc binding to Cu,Zn-superoxide dismutase have been linked to amyotrophic lateral sclerosis (ALS). (L49)

Exposure RoutesOral (L49) ; inhalation (L49) ; dermal (113)
Toxicity Summary · 1 件

Excessive zinc intake alters copper and iron absorption, most likely through competitive binding in intestinal mucosal cells. Stomach acid dissolves metallic zinc, producing zinc chloride, which is a corrosive product damaging the stomach lining. Metal fume fever is thought to be an immune response to inhaled zinc. (L48, L49, A49)

Signs and Symptoms · 1 件

Ingestion of large doses of zinc causes stomach cramps, nausea, and vomiting. Acute inhalation of large amounts of zinc causes metal fume fever, which is characterized by chills, fever, headache, weakness, dryness of the nose and throat, chest pain, and coughing. Dermal contact with zinc results in skin irritation. (L49)

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

化学と産業

薬理情報

ATC Code · 2 件

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingThere is no information.
Pharmacodynamics · 1 件

Velmanase alfa is an enzyme replacement therapy that aims to reduce oligosaccharide levels in patients with alpha-mannosidosis. In clinical trials, reduced serum oligosaccharide levels and improvements in biochemical and functional measures were seen at 18 months and for up to four years of treatment. Reversing the organ damage or showing improvements in alpha-mannosidosis becomes increasingly difficult as the accumulation of end-organ damage progresses over time. Velmanase alfa has no effects on irreversible complications of the disorder, such as skeletal deformities, dysostosis multiplex, neurological manifestations, and impaired cognitive function.

Mechanism of Action · 1 件

Alpha-mannosidosis is a rare autosomal recessive lysosomal storage disorder: it is a multi-systemic disease, characterized by a wide range of clinical manifestations including skeletal abnormalities, motor function impairment, intellectual disability, hearing loss, respiratory dysfunction, recurrent infections, and immunodeficiency usually presenting in early childhood. Alpha-mannosidosis is caused by pathogenic sequence variants in the MAN2B1 gene, leading to the deficiency of the lysosomal enzyme, alpha-mannosidase. Alpha-mannosidase is a lysosomal enzyme involved in glycoprotein catabolism. Deficient alpha-mannosidase results in the accumulation of mannose-rich oligosaccharides, causing impaired cellular function and apoptosis in all tissues. Velmanase alfa is a recombinant form of human alpha-mannosidase. Upon administration, velmanase alfa supplements or replaces natural alpha-mannosidase to properly break down hybrid and complex high-mannose oligosaccharides in the lysosome, reducing the amount of accumulated mannose-rich oligosaccharides.

Biological Half-LifeAt the end of intravenous infusion, velmanase alfa plasma concentrations fell in a biphasic fashion with a mean terminal elimination half-life of about 30 hours.
Metabolism/Metabolites · 2 件

Velmanase alfa is expected to undergo nonspecific degradation into small peptides and subsequently amino acids, similar to other natural occurring proteins.

Zinc enters the body through the lungs, skin, and gastrointestinal tract. Intestinal absorption of zinc is controlled by zinc carrier protein CRIP and metallothioneins. Zinc is widely distributed in tissues and tissues fluids, and concentrated in the liver, gastrointestinal tract, kidney, skin, lung, brain, heart, and pancreas. Zinc binds to carbonic anhydrase in erythrocytes, and to albumin, α2-macroglobulin, and amino acids in the the plasma. Albumin and amino acid bound zinc can diffuse across tissue membranes. Zinc is excreted in the urine and faeces. (L49)

用途と製造

Uses · 1 件

Zinc has many commercial uses as coatings to prevent rust, in dry cell batteries, and can be mixed with other metals to produce alloys such as brass and bronze. Zinc compounds are widely used in industry to make paint, rubber, dyes, wood preservatives, and ointments. (L49)

関連反応

1,105 件

関連ノート

読み込み中…